In recent years, there has been an explosion of interest in how fibroblasts initiate, sustain,
and resolve inflammation across disease states. Fibroblasts contain heterogeneous subsets …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by a progressive
decline in lung function and poor prognosis. The deposition of the extracellular matrix (ECM) …

Pulmonary fibrosis (PF) is an age-related interstitial lung disease that results in notable
morbidity and mortality. The Food and Drug Administration–approved drugs can decelerate …

As epigenetic modifications, lactylation and N6-methyladenosine (m6A) have attracted wide
attention. Arsenite is an environmental pollutant that has been proven to induce idiopathic …

Idiopathic pulmonary fibrosis (IPF) is a chronic irreversible interstitial lung disease
characterized by a progressive decline in lung function. The etiology of IPF is unknown …

Ethnic pharmacological relevance Pulmonary fibrosis (PF) is a fibrotic interstitial lung
disease caused by continuous damage and excessive repair of alveolar epithelial cells, the …

Cellular senescence, a characteristic sign of aging, classically refers to permanent cell
proliferation arrest and is a vital contributor to the pathogenesis of cancer and age-related …

COPD is a heterogeneous disorder that shows diverse clinical presentations (phenotypes
and “treatable traits”) and biological mechanisms (endotypes). This heterogeneity implies …

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible and fatal interstitial lung
disease of unknown cause, with a median survival of 2‑3 years. Its pathogenesis is unclear …

Idiopathic pulmonary fibrosis (IPF) is a chronic and refractory interstitial lung disease.
Although there are two approved drugs for IPF, they were not able to completely cure the …